In a recent preclinical study, a CMV-based therapeutic vaccine expressing the E6 peptide of human papillomavirus type 16 as a neo-epitope and lacking immunoevasins was generated in order to use the viral vector as an adjuvant for the presentation of endogenous tumor antigens and finally to repurpose bystander CMV-specific CD8+ T cells against the tumor [110]. The gene discussed is CD8A; the disease is neoplasm.